Table 7.
Impact of the strength of CYP2D6 inhibition on neonatal short-term outcomes.
| CYP2D6 inhibition (+) Strong + Moderate N = 18 |
CYP2D6 inhibition (+) Weak N = 20 |
P-value | |
|---|---|---|---|
| Birth Weight (g) | 2752 (2154–3902) | 2970 (2372–3530) | 0.44 |
| LFD | 2 (11%) | 2(10%) | 0.46 |
| SGA | 3 (17%) | 1 (5.0%) | 0.12 |
| Apgar score at 1 min | 8 (1–8) | 8 (4–8) | 0.0468* |
| Apgar score at 5 min | 9 (4–9) | 9 (6–9) | 0.0017* |
| Umbilical artery pH | 7.31 (7.21–7.38) | 7.29 (7.15–7.38) | 0.08 |
| NICU admission | 7 (39%) | 5 (25%) | 0.18 |
| Respiratory ventilator treatment | 4 (22%) | 2 (10%) | 0.15 |
| NAS | 2 (11%) | 3 (15%) | 0.36 |
| Congenital Anomalies | 0 (0%) | 1 (5.0%) | 0.17 |
median (range) or number (%).
LFD: large-for-date, SGA: small-for-gestational age, NICU: neonatal intensive care unit, NAS: neonatal abstinence syndrome, CYP: cytochrome P450.
* p < 0.05.